Nanoform Finland Plc (Nasdaq First North Growth Market: NANOFH, NANOFS), a medicine performance-enhancing company, on Monday announced a partnership with specialty pharma company Revio Therapeutics to co-develop and commercialise GLIORA, a nano-formulated combination of olaparib and temozolomide designed for the treatment of high-grade glioma, a fast-growing and aggressive type of brain tumour.

The therapy will be delivered locally as a long-acting, thermo-responsive hydrogel to the tumour resection site during surgery.

GLIORA aims to improve on the current oral standard-of-care temozolomide by providing targeted delivery, enhancing tumour control, and minimising systemic side effects. The inclusion of olaparib, originally developed by AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN), is expected to enhance the effects of temozolomide, originally developed by Merck & Co Inc (NYSE:MRK), through synergistic DNA damage amplification and suppression of tumour repair mechanisms.

Nanoform will apply its proprietary Controlled Expansion of Supercritical Solutions (CESS) and hydrogel technologies under GMP conditions at its Helsinki facility to create the nanoformulated product prototype. Revio will lead preclinical and clinical development and manage manufacturing and supply of the final product.

Prototype testing is already at an advanced stage, with clinical trials expected to begin in the second half of 2026. Subject to successful outcomes, commercial availability is targeted for 2029-2030. Development costs, licensing, and commercial revenues will be shared equally, with Nanoform receiving EUR1.5m in accelerated revenue-share payments.